Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

- Company to be Featured on Oct 25, 2007 -

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interesting cardiovascular projects available for partnering. VIA will be featured at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference and Lawrence Cohen, Ph.D., chief executive officer and president of the company, will be providing more details about VIA-2291 at the meeting on October 25 at 2 p.m. Eastern Time in Philadelphia.

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, and medical device and diagnostic industries. Its editorial and research staff, including the publishers of In Vivo and Startup, have chosen the top ten best compounds for licensing in each of four disease areas based on the following criteria: size of market, history of the molecule and drug, strength of the underlying science, diversity of potential indications, overall company strength and availability of multi-partnering opportunities.

"We are honored and delighted that VIA-2291 has been identified as one of the top cardiovascular drugs by the knowledgeable editorial and research staffs of the Windhover organization," said Dr. Cohen.

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... VANCOUVER , June 30, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... the first participant in its Phase 1/2 clinical ... of chronic unilateral Achilles tendinosis, has been enrolled ... to intra-tendon ultrasound-guided injections. RCT-01 is comprised of ...
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
(Date:6/29/2015)... ... ... The global microfluidics market is expected to grow at ... The market is mainly driven by the rising geriatric population, growing Asian healthcare ... adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals in ...
(Date:6/29/2015)...  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company ... and cell therapy treatments for central nervous system diseases, ... on the NASDAQ Capital Market under the symbol "CUR." ... the NYSE MKT until the market close on July ... expected to commence on July 13, 2015. ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3
... Group, Inc.,released its third annual TreatmentTrends(TM): The Use ... the management of,Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), ... responses to an online survey,completed by 100 US ... study, the majority of Rheumatologists reported an,increase in ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... scheduled to participate in the upcoming UBS Global Life,Sciences ... York City., D. Ashley Lee, executive vice president, ... will present Wednesday,September 24 at 2:30 p.m., Eastern Time., ...
... Conn., Sept. 17 MannKind Corporation,(Nasdaq: MNKD ) ... States,Food and Drug Administration to use AFRESA as the ... uh-FRESS-uh) was unveiled today by Alfred Mann,Chairman and Chief ... Danbury, Conn., location that marked the completion and,dedication of ...
Cached Biology Technology:Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis? 2CryoLife to Present at UBS Global Life Sciences Conference 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 3
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
(Date:6/9/2015)... Minn. , June 9, 2015   MedNet ... supports the entire spectrum of clinical research, will be ... eClinical technology platform at the 2015 Drug Information Association ... on June 15-17.  These presentations will include previews ... rolled out in the upcoming iMedNet 2015 ...
(Date:6/8/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of cell-free ... Cancer Monitoring SM platform will be presented at the ... San Diego, CA on June 11-12 , ... Genomics and Cancer Therapy in Salt Lake ... "We continue to advance our clinical programs and present data ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... forests, a Michigan State University (MSU) sustainability scholar proposes a ... fall in China, can you hear it elsewhere in the ... Pacific Policy Studies , MSU,s University Distinguished Professor Jianguo "Jack" ... and expand its forests even as its cities and population ...
... presence of male sperm and seminal fluid causes female worms to ... week in the journal Science . The demise of the ... the mating pool for other males. The researchers found ... to dehydrate, prematurely age and die. "Their lifespans are ...
Cached Biology News:ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3Telecoupling science shows China's forest sustainability packs global impact 2Mating is the kiss of death for certain female worms 2Mating is the kiss of death for certain female worms 3
... Sigma-Genosys offers custom peptide synthesis with a wide ... best fit your research needs. Purity: ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, ...
... liquid handling system from Molecular Devices provides ... one instrument. The system handles a variety ... washing96-, 384- and 1536-welland is the first ... has been optimized to dispense from four ...
A univariate (peak height or area) quantitative multi-component analysis package....
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: